SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 19:04:34 17/05/2024 BST | ||
| 3.72 EUR | +0.27% |
|
| Current month | -0.27% | ||
| 1 month | +9.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 3.72 | +0.27% |
| 16/05/24 | 3.71 | +1.09% |
| 15/05/24 | 3.67 | -0.54% |
| 14/05/24 | 3.69 | +0.82% |
| 13/05/24 | 3.66 | -0.81% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9JAN |
| ISIN | DE000VX9JAN0 |
| Date issued | 04/04/2022 |
| Strike | 84.48 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.8 € |
|---|---|
| Lowest since issue | 0.49 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
44.03
USD
Average target price
53.19
USD
Spread / Average Target
+20.81%
- Stock Market
- Certificates
- Certificat
